Newsstand Menu

New shape-shifting antibiotics could fight deadly infections

Image of MRSA bacteria
An illustration of deadly bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a superbug resistant to several kinds of antibiotics. According to one estimate, it killed more than 100,000 people worldwide in 2019. Image: 漏 Kateryna_Kon 锘库 stock.adobe.com

In the United States alone, drug-resistant bacteria and fungi infect almost 3 million people per year and . Antibiotics are essential and effective, but in recent years overuse has led to some bacteria developing resistance to them. The infections are so difficult to treat, the World Health Organization deemed antibiotic resistance a top 10 global public health threat.

Now, Professor John E. Moses at Laboratory(麻豆传媒社区) has created a new weapon against these drug-resistant superbugs鈥攁n antibiotic that can shape-shift by rearranging its atoms.

Moses came up with the idea of shape-shifting antibiotics while observing tanks in military training exercises. With rotating turrets and nimble movements, the tanks could respond quickly to possible threats.

This animated video illustrates how the Moses team is reengineering existing antibiotics to better fight and kill drug-resistant bacteria.

A few years later, Moses learned of a molecule called bullvalene. Bullvalene is a fluxional molecule, meaning its atoms can swap positions. This gives it a changing shape with over a million possible configurations鈥攅xactly the fluidity Moses was looking for.

Several bacteria, including MRSA, VRSA, and VRE, have developed resistance to a potent antibiotic called vancomycin, used to treat everything from skin infections to meningitis. Moses thought he could improve the drug鈥檚 bacteria-fighting performance by combining it with bullvalene.

He turned to click chemistry, a Nobel Prize鈥搘inning class of fast, high-yielding chemical reactions that 鈥渃lick鈥 molecules together reliably. This makes the reactions more efficient for wide-scale use.

鈥淐lick chemistry is great,鈥 says Moses, who studied this revolutionary development under two-time Nobel laureate K. Barry Sharpless. 鈥淚t gives you certainty and the best chance you鈥檝e got of making complex things.鈥

Using this technique, Moses and his colleagues created a new antibiotic with two vancomycin 鈥渨arheads鈥 and a fluctuating bullvalene center.

Image of new antibiotic chemical structure
The chemical structure of the new antibiotic was designed by Moses and synthetically assembled by his lab. Dr. Thomas Fallon, Moses鈥 collaborator at the University of Newcastle, Australia, provided the shape-shifting bullvalene core. Moses says one commenter called the study 鈥減robably the 鈥榗oolest鈥 and most complex natural product derivative paper I鈥檝e come across.鈥

Moses tested the new drug in collaboration with Dr. Tatiana Soares da-Costa (University of Adelaide). The researchers gave the drug to VRE-infected wax moth larvae, which are commonly used to test antibiotics. They found the shape-shifting antibiotic significantly more effective than vancomycin at clearing the deadly infection. Additionally, the bacteria didn鈥檛 develop resistance to the new antibiotic.

Researchers can use click chemistry with shape-shifting antibiotics to create a multitude of new drugs, Moses explains. Such weapons against infection may even be key to our species鈥 survival and evolution.

鈥淚f we can invent molecules that mean the difference between life and death,鈥 he says, 鈥渢hat鈥檇 be the greatest achievement ever.鈥

Written by: Margaret Osborne, Science Writer | publicaffairs@cshl.edu | 516-367-8455


Funding

National Cancer Institute, Australian Research Council, National Health and Medical Research Council of Australia, New Zealand Marsden Fund, Royal Society University Research Fellowship, Wolfson College, Medical Research Council U.K.

Citation

Ottonello, A., et al., 鈥淪hapeshifting bullvalene-linked vancomycin dimers as effective antibiotics against multidrug-resistant gram-positive bacteria鈥, Proceedings of the National Academy of Sciences, April 3, 2023. DOI:

Stay informed

Sign up for our newsletter to get the latest discoveries, upcoming events, videos, podcasts, and a news roundup delivered straight to your inbox every month.

  Newsletter Signup

Principal Investigator

John Moses

John Moses

Professor
Cancer Center Member
Ph.D. (DPhil), University of Oxford, 2004

Tags